Net debt/EBITDA společnosti Neovacs S.A
Jaká je hodnota metriky Net debt/EBITDA společnosti Neovacs S.A?
Hodnota metriky Net debt/EBITDA společnosti Neovacs S.A. je 2.65
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Neovacs S.A
Čemu se věnuje společnost Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou net debt/ebitda podobnou společnosti Neovacs S.A
- Hodnota metriky Net debt/EBITDA společnosti Okta je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Moneta Porcupine Mines je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Hallador Co je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Honeywell International je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Marinus Pharmaceuticals je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Linamar je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Neovacs S.A je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Yatsen Ltd je 2.65
- Hodnota metriky Net debt/EBITDA společnosti Genworth Mortgage Insurance Australia je 2.66
- Hodnota metriky Net debt/EBITDA společnosti Minerva Neurosciences Inc je 2.66
- Hodnota metriky Net debt/EBITDA společnosti Lawson Products je 2.66
- Hodnota metriky Net debt/EBITDA společnosti Calibre Mining je 2.66
- Hodnota metriky Net debt/EBITDA společnosti Miniluxe Corp je 2.66